Type 2 Diabetes Next Generation Therapeutics Create Vast Opportunities in Europe, says Frost & Sullivan

Description

Type 2 Diabetes Next GenerationType 2 Diabetes Next Generation Therapeutics Create Vast Opportunities in Europe, says Frost & Sullivan PR Newswire LONDON, Feb. 11, 2014 -- Research advances in novel pathways produce innovative antidiabetic drugs, which will pave the way for successful market penetration Type 2 diabetes is one of the most significant global health concerns of modern times. According to the International Diabetes Federation, more than 55 million people have been diagnosed with diabetes in Europe in 2012, and this number is expected to rise to 64 million by 2030. A recent research by Frost & Sullivan, "Global Type 2 Diabetes Therapeutics Market," covers the European region in detail, as well as other key markets worldwide. The European market earned revenues for €9.50 billion in 2009 and is estimated to reach €15.46 billion in 2017, at a CAGR of 3.8 percent. Due to the chronic nature of the disease and the numerous co-morbidities that make patients particularly sensitive to long-term drug safety, the clinical and regulatory hurdles are considerable. However, the immense size of the potential market has stimulated a vast and growing pipeline of prospected new therapies aimed at addressing the unmet needs of tighter glucose control, improved safety profiles, and greater convenience to patients.

Informations

• Publié par: frost-sullivan
• Publié le: 11 février 2014
• Nombre de lectures: 5
• Langue: English

Extrait

Type 2 Diabetes Next Generation Therapeutics Create Vast Opportunities in Europe, says Frost & Sullivan

PR Newswire

LONDON, Feb. 11, 2014

-- Research advances in novel pathways produce innovative antidiabetic drugs, which will pave the way for successful market penetration

Type 2 diabetes is one of the most significant global health concerns of modern times. According to the International Diabetes Federation, more than 55 million people have been diagnosed with diabetes in Europe in 2012, and this number is expected to rise to 64 million by 2030.